补体是感染性脓毒症有害事件的主要诱导因素
本文综述了感染性脓毒症中补体激活的证据:人类和小鼠的多微生物脓毒症均出现强烈补体激活,主要产物包括C5a过敏毒素及其受体(C5aR1、C5aR2)以及终末补体激活产物C5b-9。这些产物导致先天免疫系统功能障碍——早期过度促炎反应后免疫功能下降,继而免疫抑制和多器官功能障碍;C5a还激活中性粒细胞和巨噬细胞,最终出现具有强促炎和促血栓活性的细胞外组蛋白。C5b-9触发上皮和内皮细胞内钙流,组蛋白激活NLRP3炎症小体;C5a激活心肌细胞MAPK和Akt信号通路,导致细胞内钙蓄积、动作电位缺陷和细胞功能障碍,引起心脏及其他器官功能障碍。阻断这些补体依赖产物的在体干预可减轻脓毒症严重程度,C5a及其受体、组蛋白及MAPK通路是明显靶点;C5阻断(eculizumab)因损害对奈瑟菌和肺炎球菌的防御且需预先免疫而受限,C5aR小分子阻断剂正在研发中,可能对脓毒症治疗有效。
要点
- 人类和小鼠多微生物脓毒症均出现强烈补体激活,主要产物为C5a及其受体C5aR1/C5aR2,以及终末产物C5b-9。
- C5a驱动中性粒细胞和巨噬细胞激活,最终出现细胞外组蛋白,后者具有强促炎和促血栓活性。
- C5b-9触发上皮和内皮细胞内钙流;组蛋白激活NLRP3炎症小体,其产物可损伤细胞。
- C5a激活心肌细胞MAPK和Akt信号通路,导致细胞内钙蓄积、动作电位缺陷和细胞功能障碍,引起心脏及其他器官功能障碍,心脏功能障碍可用ECHO-Doppler参数定量。
- 阻断补体依赖产物的在体干预可减轻脓毒症严重程度;C5a及其受体、组蛋白及MAPK通路是明显靶点。
适用人群与场景
- 人类感染性脓毒症患者和小鼠多微生物脓毒症模型。
处置流程与药物剂量
- C5阻断已用于脓毒症考虑,但FDA批准的抗体eculizumab已知损害对奈瑟菌和肺炎球菌的防御,且临床使用前需免疫接种。
- C5aR小分子阻断剂目前正在研发中,可能对脓毒症治疗有效。
研究设计与关键结果
- 综述指出:人类和小鼠多微生物脓毒症均导致强烈补体激活,主要产物包括C5a过敏毒素及其受体C5aR1和C5aR2,以及可能的终末补体激活产物C5b-9。
- 补体产物导致先天免疫系统功能障碍:早期促炎反应过度,随后先天免疫系统下降,导致免疫抑制和多器官功能障碍。
- 脓毒症中C5a生成导致中性粒细胞和巨噬细胞激活,最终出现细胞外组蛋白,具有强促炎和促血栓活性。
- C5b-9触发上皮和内皮细胞内钙流;组蛋白激活NLRP3炎症小体,其产物可损伤细胞。
- C5a激活心肌细胞MAPK和Akt信号通路,导致细胞内钙蓄积、动作电位缺陷和显著细胞功能障碍,引起心脏及其他器官功能障碍;心脏功能障碍可用ECHO-Doppler参数定量。
- 在体阻断这些补体依赖产物可减轻脓毒症严重程度;明显靶点为C5a及其受体、组蛋白,可能还有MAPK通路。
证据类型、等级与局限
- 证据类型:综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 补体激活产物(C5a、C5aR1/C5aR2、C5b-9、组蛋白)是感染性脓毒症器官功能障碍的潜在治疗靶点。
- C5阻断(eculizumab)因损害对奈瑟菌和肺炎球菌的防御且需预先免疫,临床使用受限。
- C5aR小分子阻断剂正在研发中,可能对脓毒症治疗有效。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
There is abundant evidence that infectious sepsis both in humans and mice with polymicrobial sepsis results in robust activation of complement. Major complement activation products involved in sepsis include C5a anaphylatoxin and its receptors (C5aR1 and C5aR2) and, perhaps, the terminal complement activation product, C5b-9. These products (and others) also cause dysfunction of the innate immune system, with exaggerated early proinflammatory responses, followed by decline of the innate immune system, leading to immunosuppression and multiorgan dysfunction. Generation of C5a during sepsis also leads to activation of neutrophils and macrophages and ultimate appearance of extracellular histones, which have powerful proinflammatory and prothrombotic activities. The distal complement activation product, C5b-9, triggers intracellular Ca fluxes in epithelial and endothelial cells. Histones activate the NLRP3 inflammasome, products of which can damage cells. C5a also activates MAPKs and Akt signaling pathways in cardiomyocytes, causing buildup of [Ca]i, defective action potentials and substantial cell dysfunction, resulting in cardiac and other organ dysfunction. Cardiac dysfunction can be quantitated by ECHO-Doppler parameters. In vivo interventions that block these complement-dependent products responsible for organ dysfunction in sepsis reduce the intensity of sepsis. The obvious targets in sepsis are C5a and its receptors, histones, and perhaps the MAPK pathways. Blockade of C5 has been considered in sepsis, but the FDA-approved antibody (eculizumab) is known to compromise defenses against neisseria and pneumonococcal bacteria, and requires immunization before the mAb to C5 can be used clinically. Small molecular blocking agents for C5aRs are currently in development and may be therapeutically effective for treatment of sepsis.
参考来源
- Fattahi F, Zetoune FS, Ward PA, et al. Complement as a Major Inducer of Harmful Events in Infectious Sepsis. Shock. 2020. PMID: 32187106. doi:10.1097/SHK.0000000000001531
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。